spironolactone has been researched along with Kidney Diseases in 142 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
Excerpt | Relevance | Reference |
---|---|---|
"Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF)." | 9.41 | Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. ( Beldhuis, IE; Bristow, M; Claggett, B; Damman, K; Desai, AS; Fang, JC; Fleg, JL; Lewis, EF; McKinlay, S; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Vardeny, O; Voors, AA, 2021) |
"Spironolactone reduced BP and urinary albumin, improve fibrosis and inflammation, whereas slightly increases the glycosylated haemoglobin and serum creatinine in patients with hypertension and diabetes." | 9.12 | A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. ( Abudoyreyimu, R; Heizati, M; Li, N; Lin, M; Nurula, M; Wang, L; Wang, Z; Wu, Z; Yang, Z, 2021) |
"Treatment with spironolactone (SPL) is beneficial in patients with severe congestive heart failure (CHF)." | 7.72 | How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? ( Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR; Svensson, M, 2004) |
"Six adult patients (4 females and 2 males, age range 26-57 years) with Gitelman's syndrome (GS) were treated with spironolactone 200-300 mg/day (n = 5) and/or amiloride 10-30 mg/day (n = 3) for 1-18 months." | 7.69 | Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ( Colussi, G; De Ferrari, ME; Macaluso, M; Minetti, L; Rombolà, G, 1994) |
"Aldosterone plays a central role in the regulation of sodium and potassium homoeostasis by binding to the mineralocorticoid receptor and contributes to kidney and cardiovascular damage." | 5.43 | Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice. ( Enomoto, D; Higaki, J; Kukida, M; Miyoshi, K; Nagao, T; Okamura, H; Okura, T; Pei, Z; Tanino, A, 2016) |
"Treatment of heart failure with preserved ejection fraction (HFpEF) with spironolactone is associated with lower risk of heart failure hospitalization (HFH) but increased risk of worsening renal function (WRF)." | 5.41 | Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. ( Beldhuis, IE; Bristow, M; Claggett, B; Damman, K; Desai, AS; Fang, JC; Fleg, JL; Lewis, EF; McKinlay, S; Myhre, PL; O'Meara, E; Pfeffer, MA; Pitt, B; Shah, SJ; Solomon, SD; Vardeny, O; Voors, AA, 2021) |
" Treatment with spironolactone did not affect the biomarker of fibrosis Gal-3 in AF patients." | 5.41 | Galectin-3 in patients with atrial fibrillation and restored sinus rhythm. ( Angelov, A; Bocheva, Y; Chervenkov, T; Kisheva, A; Yotov, Y, 2021) |
"Spironolactone treatment markedly suppressed osteopontin expression." | 5.35 | Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. ( Hayashida, H; Hirakata, H; Iida, M; Ikeda, H; Masutani, K; Toyonaga, J; Tsuruya, K, 2009) |
"We performed this study to assess whether low dose spironolactone could be administered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardiovascular function and reduce hospitalization without inducing hyperkalemia." | 5.14 | Spironolactone in chronic hemodialysis patients improves cardiac function. ( Eshaghian, A; Garakyaraghi, M; Ghassami, M; Mortazavi, M; Pourmoghadas, A; Seirafian, S; Shahidi, S; Taheri, S, 2009) |
"Spironolactone reduced BP and urinary albumin, improve fibrosis and inflammation, whereas slightly increases the glycosylated haemoglobin and serum creatinine in patients with hypertension and diabetes." | 5.12 | A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes. ( Abudoyreyimu, R; Heizati, M; Li, N; Lin, M; Nurula, M; Wang, L; Wang, Z; Wu, Z; Yang, Z, 2021) |
"This study shows that spironolactone may effectively reduce proteinuria in patients with CKD." | 5.11 | Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. ( Bianchi, S; Bigazzi, R; Campese, VM, 2005) |
"To compare the efficacy of three commonly used diuretic regimens in the treatment of ascites, we randomized 90 patients to three treatment groups: Sequential Spironolactone (spironolactone followed by furosemide if necessary), Combination (spironolactone and furosemide in combination), and Furosemide (furosemide given alone)." | 5.05 | Diuresis in the ascitic patient: a randomized controlled trial of three regimens. ( Fogel, MR; Gregory, PB; Knauer, CM; Miller, RG; Neal, EA; Sawhney, VK, 1981) |
"Eplerenone, an aldosterone receptor antagonist from Searle is being developed as a potential treatment for renal disease, congestive heart failure and hypertension." | 4.81 | Eplerenone (GD Searle & Co). ( Krum, H; Martin, J, 2001) |
"Eplerenone is a selective aldosterone blocker that effectively lowers BP in both white and black patients with hypertension and provides meaningful further antihypertensive efficacy when added to patients whose hypertension is inadequately controlled by angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers." | 4.81 | Clinical implications of aldosterone blockade. ( Weber, MA, 2002) |
"Among patients with DKD and hypertension, the short-term use of MRAs, either spironolactone or eplerenone, in combination with ACEI/ARBs, was not associated with lower risk of cardiovascular or kidney outcomes compared with ACEI/ARB monotherapy." | 4.02 | Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. ( An, J; Niu, F; Sim, JJ, 2021) |
" We investigated whether spironolactone, an aldosterone receptor blocker, attenuated isoprenaline (Iso)-induced heart failure in rats and also studied the mechanism for the same." | 3.83 | Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats. ( Chen, S; Guo, Z; Liu, J; Xi, D; Zhao, J; Zhou, H, 2016) |
"We prospectively studied the effects of adding spironolactone (25 mg/day) to 87 patients who maintained proteinuria higher than 1 g/day in spite of renin-angiotensin system blockade." | 3.79 | Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. ( Egido, J; Gutiérrez, E; Gutiérrez-Solís, E; Huerta, A; Millet, VG; Morales, E; Praga, M; Rojas-Rivera, J, 2013) |
" Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection." | 3.76 | Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. ( Arhancet, GB; Blinn, JR; Chen, X; Collins, JT; Dietz, JD; Garland, DJ; Heron, MI; Hockerman, SL; Homer, BL; Hu, X; Huang, HC; Long, SA; Mahoney, MW; McGee, KF; Meyers, MJ; Payne, MA; Reitz, DB; Rico, JR; Wendling, JM; Yang, S, 2010) |
"Treatment with spironolactone (SPL) is beneficial in patients with severe congestive heart failure (CHF)." | 3.72 | How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? ( Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR; Svensson, M, 2004) |
" The lack of therapeutic response to spironolactone, with a good response to amiloride and recurrence of hypertension and metabolic alkalosis after amiloride cessation that was subsequently treated with amiloride, established the diagnosis of Liddle syndrome." | 3.71 | Liddle syndrome in a newborn infant. ( Assadi, FK; Kimura, RE; Patel, S; Subramanian, U, 2002) |
"Six adult patients (4 females and 2 males, age range 26-57 years) with Gitelman's syndrome (GS) were treated with spironolactone 200-300 mg/day (n = 5) and/or amiloride 10-30 mg/day (n = 3) for 1-18 months." | 3.69 | Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ( Colussi, G; De Ferrari, ME; Macaluso, M; Minetti, L; Rombolà, G, 1994) |
"The influence of renal impairment on the pharmacokinetics of eplerenone following single and multiple dosing was evaluated." | 2.71 | Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. ( Ravis, WR; Reid, S; Sica, DA; Tolbert, DS, 2005) |
"Aldosterone has been overlooked as a mediator of RAAS escape and a key factor in target-organ injury despite the use of available RAAS blockers." | 2.42 | RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. ( Lakkis, J; Lu, WX; Weir, MR, 2003) |
"Treatment with losartan or spironolactone alone significantly reduced various CKD-associated features." | 1.56 | Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats. ( Aggarwal, D; Singh, G, 2020) |
"Aldosterone plays a central role in the regulation of sodium and potassium homoeostasis by binding to the mineralocorticoid receptor and contributes to kidney and cardiovascular damage." | 1.43 | Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice. ( Enomoto, D; Higaki, J; Kukida, M; Miyoshi, K; Nagao, T; Okamura, H; Okura, T; Pei, Z; Tanino, A, 2016) |
"Finerenone reduced cardiac hypertrophy, plasma prohormone of brain natriuretic peptide, and proteinuria more efficiently than eplerenone when comparing equinatriuretic doses." | 1.40 | Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. ( Albrecht-Küpper, B; Bärfacker, L; Delbeck, M; Eitner, F; Hartmann, E; Kolkhof, P; Kretschmer, A; Schäfer, S; Steinke, W, 2014) |
"Spironolactone treatment prevented Th17 cell activation and increased numbers of forkhead box P3-positive cells relative to DOCA-salt rats." | 1.40 | Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. ( Alzamora, R; Amador, CA; Barrientos, V; Carrasco, L; Figueroa, F; González, M; Herrada, AA; Kalergis, AM; Michea, L; Peña, J; Valdés, S, 2014) |
"Hypertension is a major risk factor for the development and progression of chronic kidney disease (CKD)." | 1.38 | Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. ( Acelajado, MC; Calhoun, DA; Cartmill, FR; Cofield, SS; Dell'Italia, LJ; Dudenbostel, T; Oparil, S; Pisoni, R, 2012) |
"Patients with aldosteronism had relative estimated hyperfiltration than patients with EH." | 1.37 | Kidney impairment in primary aldosteronism. ( Chang, HW; Cheng, BW; Chiang, CK; Chiu, JS; Chu, TS; Chueh, SC; Ho, YL; Hu, FC; Huang, KH; Kuo, CC; Lin, CY; Lin, JW; Lin, LY; Lin, SL; Lin, YH; Liu, KL; Tsai, CT; Wang, SM; Wu, KD; Wu, VC; Yang, SY; Yen, RF, 2011) |
"Spironolactone treatment prevents renal damage induced by ischemia-reperfusion (I/R), suggesting that renoprotection conferred by spironolactone is mediated by mineralocorticoid receptor (MR) blockade." | 1.35 | Adrenalectomy prevents renal ischemia-reperfusion injury. ( Bobadilla, NA; Cruz, C; Gamba, G; Ramírez, V; Trujillo, J; Uribe, N; Valdes, R, 2009) |
"Spironolactone treatment markedly suppressed osteopontin expression." | 1.35 | Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. ( Hayashida, H; Hirakata, H; Iida, M; Ikeda, H; Masutani, K; Toyonaga, J; Tsuruya, K, 2009) |
"Patients with primary aldosteronism were compared with 100 patients with essential hypertension, matched for severity and duration of hypertension." | 1.33 | Long-term renal outcomes in patients with primary aldosteronism. ( Baroselli, S; Catena, C; Colussi, GL; Lapenna, R; Nadalini, E; Novello, M; Sechi, LA, 2006) |
"Aldosterone treatment of cells resulted in significant up-regulation of several genes within 1 hour, with sgk, p21/waf1, gadd45, and gadd153 being the most significant ones." | 1.32 | Early aldosterone up-regulated genes: new pathways for renal disease? ( Christ, M; Falkenstein, E; Feuring, M; Hafner, M; Kellner, M; Lösel, R; Peiter, A; Wehling, M, 2003) |
"Spironolactone treatment decreased PAI-1 immunoreactivity and reduced in a dose-dependent fashion cardiac and renal damage." | 1.32 | Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. ( Adler, GK; Jonasson, L; Martinez-Vasquez, D; Mukasa, K; Oestreicher, EM; Roubsanthisuk, W; Stone, JR, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 55 (38.73) | 18.7374 |
1990's | 3 (2.11) | 18.2507 |
2000's | 51 (35.92) | 29.6817 |
2010's | 26 (18.31) | 24.3611 |
2020's | 7 (4.93) | 2.80 |
Authors | Studies |
---|---|
Meyers, MJ | 1 |
Arhancet, GB | 1 |
Hockerman, SL | 1 |
Chen, X | 1 |
Long, SA | 1 |
Mahoney, MW | 1 |
Rico, JR | 1 |
Garland, DJ | 1 |
Blinn, JR | 1 |
Collins, JT | 1 |
Yang, S | 1 |
Huang, HC | 1 |
McGee, KF | 1 |
Wendling, JM | 1 |
Dietz, JD | 1 |
Payne, MA | 1 |
Homer, BL | 1 |
Heron, MI | 1 |
Reitz, DB | 1 |
Hu, X | 1 |
An, J | 1 |
Niu, F | 1 |
Sim, JJ | 1 |
Choy, M | 1 |
Zhen, Z | 1 |
Dong, B | 1 |
Chen, C | 1 |
Dong, Y | 1 |
Liu, C | 1 |
Liang, W | 1 |
Xue, R | 1 |
Williams, GH | 1 |
Aggarwal, D | 1 |
Singh, G | 1 |
Leader, CJ | 1 |
Kelly, DJ | 1 |
Sammut, IA | 1 |
Wilkins, GT | 1 |
Walker, RJ | 1 |
Beldhuis, IE | 1 |
Myhre, PL | 1 |
Bristow, M | 1 |
Claggett, B | 1 |
Damman, K | 1 |
Fang, JC | 1 |
Fleg, JL | 1 |
McKinlay, S | 1 |
Lewis, EF | 1 |
O'Meara, E | 1 |
Pitt, B | 2 |
Shah, SJ | 1 |
Vardeny, O | 1 |
Voors, AA | 1 |
Pfeffer, MA | 1 |
Solomon, SD | 1 |
Desai, AS | 1 |
Lin, M | 1 |
Heizati, M | 1 |
Wang, L | 1 |
Nurula, M | 1 |
Yang, Z | 1 |
Wang, Z | 3 |
Abudoyreyimu, R | 1 |
Wu, Z | 1 |
Li, N | 1 |
Kisheva, A | 1 |
Yotov, Y | 1 |
Chervenkov, T | 1 |
Angelov, A | 1 |
Bocheva, Y | 1 |
Maiolino, G | 1 |
Calò, LA | 1 |
Amador, CA | 1 |
Barrientos, V | 1 |
Peña, J | 1 |
Herrada, AA | 1 |
González, M | 1 |
Valdés, S | 1 |
Carrasco, L | 1 |
Alzamora, R | 1 |
Figueroa, F | 1 |
Kalergis, AM | 1 |
Michea, L | 1 |
Kolkhof, P | 1 |
Delbeck, M | 1 |
Kretschmer, A | 1 |
Steinke, W | 1 |
Hartmann, E | 1 |
Bärfacker, L | 1 |
Eitner, F | 1 |
Albrecht-Küpper, B | 1 |
Schäfer, S | 1 |
Sun, QL | 1 |
Li, M | 1 |
Rui, HL | 1 |
Chen, YP | 1 |
Stewart Coats, AJ | 1 |
Shewan, L | 1 |
Martín-Fernández, B | 2 |
Rubio-Navarro, A | 1 |
Cortegano, I | 1 |
Ballesteros, S | 1 |
Alía, M | 1 |
Cannata-Ortiz, P | 1 |
Olivares-Álvaro, E | 1 |
Egido, J | 2 |
de Andrés, B | 1 |
Gaspar, ML | 1 |
de Las Heras, N | 2 |
Lahera, V | 2 |
Moreno, JA | 1 |
Zhou, H | 1 |
Xi, D | 1 |
Liu, J | 2 |
Zhao, J | 1 |
Chen, S | 2 |
Guo, Z | 1 |
Tanino, A | 1 |
Okura, T | 1 |
Nagao, T | 1 |
Kukida, M | 1 |
Pei, Z | 1 |
Enomoto, D | 1 |
Miyoshi, K | 1 |
Okamura, H | 1 |
Higaki, J | 1 |
Renke, M | 2 |
Tylicki, L | 2 |
Knap, N | 1 |
Rutkowski, P | 2 |
Neuwelt, A | 1 |
Larczynski, W | 2 |
Wozniak, M | 1 |
Rutkowski, B | 2 |
Ikeda, H | 1 |
Tsuruya, K | 1 |
Toyonaga, J | 1 |
Masutani, K | 1 |
Hayashida, H | 1 |
Hirakata, H | 1 |
Iida, M | 1 |
Kiyomoto, H | 2 |
Rafiq, K | 2 |
Mostofa, M | 1 |
Nishiyama, A | 4 |
Brem, AS | 2 |
Lea, WB | 1 |
Kwak, ES | 1 |
Luther, JM | 2 |
Fowler, SM | 1 |
Ma, J | 1 |
Fogo, AB | 2 |
Brown, NJ | 2 |
Preston, RA | 1 |
Afshartous, D | 1 |
Garg, D | 1 |
Medrano, S | 1 |
Alonso, AB | 1 |
Rodriguez, R | 1 |
Taheri, S | 1 |
Mortazavi, M | 1 |
Shahidi, S | 1 |
Pourmoghadas, A | 1 |
Garakyaraghi, M | 1 |
Seirafian, S | 1 |
Eshaghian, A | 1 |
Ghassami, M | 1 |
van den Hoven, MJ | 1 |
Waanders, F | 1 |
Rops, AL | 1 |
Kramer, AB | 1 |
van Goor, H | 1 |
Berden, JH | 1 |
Navis, G | 1 |
van der Vlag, J | 1 |
Becker, GJ | 1 |
Hewitson, TD | 1 |
Chrysostomou, A | 2 |
Du, J | 1 |
Fan, YY | 1 |
Hitomi, H | 2 |
Kimura, S | 1 |
Kong, CZ | 1 |
Noma, T | 1 |
Kohno, M | 1 |
Nakano, D | 2 |
Kandula, P | 1 |
Shah, R | 1 |
Ramírez, V | 3 |
Trujillo, J | 2 |
Valdes, R | 1 |
Uribe, N | 4 |
Cruz, C | 3 |
Gamba, G | 4 |
Bobadilla, NA | 4 |
Nemeth, Z | 1 |
Kokeny, G | 1 |
Godo, M | 1 |
Mózes, M | 1 |
Rosivall, L | 1 |
Gross, ML | 1 |
Ritz, E | 1 |
Hamar, P | 1 |
Arias-Loza, PA | 1 |
Muehlfelder, M | 1 |
Elmore, SA | 1 |
Maronpot, R | 1 |
Hu, K | 1 |
Blode, H | 1 |
Hegele-Hartung, C | 1 |
Fritzemeier, KH | 1 |
Ertl, G | 1 |
Pelzer, T | 1 |
Lopes, R | 1 |
Lourenco, P | 1 |
Mascarenhas, J | 1 |
Azevedo, A | 1 |
Bettencourt, P | 1 |
Mizuguchi, Y | 1 |
Ichihara, A | 1 |
Seki, Y | 1 |
Sakoda, M | 1 |
Kurauchi-Mito, A | 1 |
Narita, T | 1 |
Kinouchi, K | 1 |
Bokuda, K | 1 |
Itoh, H | 1 |
Bianchi, S | 2 |
Bigazzi, R | 2 |
Campese, VM | 2 |
Ando, K | 1 |
Ohtsu, H | 1 |
Arakawa, Y | 1 |
Kubota, K | 1 |
Yamaguchi, T | 1 |
Nagase, M | 3 |
Yamada, A | 1 |
Fujita, T | 4 |
Funder, JW | 1 |
Edwards, NC | 1 |
Ferro, CJ | 1 |
Kirkwood, H | 1 |
Chue, CD | 1 |
Young, AA | 1 |
Stewart, PM | 1 |
Steeds, RP | 1 |
Townend, JN | 1 |
Abolghasmi, R | 1 |
Taziki, O | 1 |
Wu, VC | 1 |
Yang, SY | 1 |
Lin, JW | 1 |
Cheng, BW | 1 |
Kuo, CC | 1 |
Tsai, CT | 1 |
Chu, TS | 1 |
Huang, KH | 1 |
Wang, SM | 1 |
Lin, YH | 1 |
Chiang, CK | 1 |
Chang, HW | 1 |
Lin, CY | 1 |
Lin, LY | 1 |
Chiu, JS | 1 |
Hu, FC | 1 |
Chueh, SC | 1 |
Ho, YL | 1 |
Liu, KL | 1 |
Lin, SL | 1 |
Yen, RF | 1 |
Wu, KD | 1 |
Miana, M | 1 |
Rodriguez, C | 1 |
Sanz-Rosa, D | 1 |
Mezzano, S | 1 |
Martinez-Gonzalez, J | 1 |
Cachofeiro, V | 1 |
Fang, Z | 1 |
Zhang, C | 1 |
He, F | 1 |
Sun, X | 1 |
Zhu, Z | 1 |
Meng, X | 1 |
Pisoni, R | 1 |
Acelajado, MC | 1 |
Cartmill, FR | 1 |
Dudenbostel, T | 1 |
Dell'Italia, LJ | 1 |
Cofield, SS | 1 |
Oparil, S | 1 |
Calhoun, DA | 1 |
Ma, TK | 1 |
Szeto, CC | 1 |
Luo, P | 1 |
Cohen, SE | 1 |
Kim, HS | 1 |
Morales, E | 1 |
Millet, VG | 1 |
Rojas-Rivera, J | 1 |
Huerta, A | 1 |
Gutiérrez, E | 1 |
Gutiérrez-Solís, E | 1 |
Praga, M | 1 |
Assadi, FK | 1 |
Kimura, RE | 1 |
Subramanian, U | 1 |
Patel, S | 1 |
Obialo, CI | 1 |
Ofili, EO | 1 |
Mirza, T | 1 |
Weber, MA | 1 |
Feria, I | 1 |
Pichardo, I | 1 |
Juárez, P | 1 |
González, MA | 1 |
García-Torres, R | 1 |
López-Casillas, F | 1 |
McMahon, EG | 1 |
Lakkis, J | 1 |
Lu, WX | 1 |
Weir, MR | 1 |
Kellner, M | 1 |
Peiter, A | 1 |
Hafner, M | 1 |
Feuring, M | 1 |
Christ, M | 1 |
Wehling, M | 1 |
Falkenstein, E | 1 |
Lösel, R | 1 |
NADASDI, M | 1 |
MANNING, RT | 1 |
BEHRLE, FC | 1 |
SJOBERG, WE | 1 |
KREISLE, JE | 1 |
BUGNON, C | 1 |
MOREAU, N | 1 |
LENYS, R | 1 |
CATTANEO, G | 1 |
DE LUCA, S | 1 |
THAYER, JM | 1 |
HEALY, FA | 1 |
DUNLOP, D | 1 |
BAGROS, P | 1 |
METCALF, MG | 1 |
PAVER, WK | 1 |
PAULINE, GJ | 1 |
MAHER, JF | 1 |
SCHREINER, GE | 1 |
SLATON, PE | 1 |
BIGLIERI, EG | 1 |
Oestreicher, EM | 1 |
Martinez-Vasquez, D | 1 |
Stone, JR | 1 |
Jonasson, L | 1 |
Roubsanthisuk, W | 1 |
Mukasa, K | 1 |
Adler, GK | 1 |
Svensson, M | 3 |
Gustafsson, F | 3 |
Galatius, S | 3 |
Hildebrandt, PR | 3 |
Atar, D | 3 |
Ali, BH | 1 |
Al-Qarawi, AA | 1 |
Mahmoud, OM | 1 |
Hashad, M | 1 |
Nitta, K | 1 |
Uchida, K | 1 |
Nihei, H | 1 |
Newsome, BB | 1 |
Warnock, DG | 1 |
Lenz, T | 1 |
Cordaillat, M | 1 |
Rugale, C | 1 |
Casellas, D | 1 |
Mimran, A | 1 |
Jover, B | 1 |
Freedman, DB | 1 |
Housley, D | 1 |
Ravis, WR | 1 |
Reid, S | 1 |
Sica, DA | 1 |
Tolbert, DS | 1 |
Kitamura, K | 1 |
Tomita, K | 1 |
Abe, Y | 1 |
Suzuki, A | 1 |
Yoshida, M | 1 |
Miura, Y | 1 |
Oiso, Y | 1 |
Sechi, LA | 1 |
Novello, M | 1 |
Lapenna, R | 1 |
Baroselli, S | 1 |
Nadalini, E | 1 |
Colussi, GL | 1 |
Catena, C | 1 |
Pérez-Rojas, J | 1 |
Blanco, JA | 1 |
Vaidya, VS | 1 |
Bonventre, JV | 1 |
Tojo, A | 1 |
Onozato, ML | 1 |
Asaba, K | 1 |
Mejía-Vilet, JM | 1 |
Matsui, H | 1 |
Shibata, S | 1 |
Gotoda, T | 1 |
Furumatsu, Y | 1 |
Nagasawa, Y | 1 |
Tomida, K | 1 |
Mikami, S | 1 |
Kaneko, T | 1 |
Okada, N | 1 |
Tsubakihara, Y | 1 |
Imai, E | 1 |
Shoji, T | 1 |
Aleksandrowicz, E | 1 |
Lysiak-Szydlowska, W | 1 |
Maebashi, M | 1 |
Yoshinaga, K | 1 |
Bufalari, A | 1 |
Meloni, G | 1 |
Siegers, CP | 1 |
Klaassen, CD | 1 |
Morgan, T | 1 |
Carney, S | 1 |
Myers, J | 1 |
Lewy, JE | 1 |
Fogel, MR | 1 |
Sawhney, VK | 1 |
Neal, EA | 1 |
Miller, RG | 1 |
Knauer, CM | 1 |
Gregory, PB | 1 |
Holzgreve, H | 1 |
Colussi, G | 1 |
Rombolà, G | 1 |
De Ferrari, ME | 1 |
Macaluso, M | 1 |
Minetti, L | 1 |
Greene, EL | 1 |
Kren, S | 1 |
Hostetter, TH | 1 |
Delyani, JA | 1 |
Epstein, M | 1 |
Becker, G | 1 |
Martin, J | 1 |
Krum, H | 1 |
Ahmida, MH | 1 |
Abdel-Gayoum, AA | 1 |
El-Fakhri, MM | 1 |
Epstein, FH | 1 |
Wilkinson, SP | 1 |
Wheeler, PG | 1 |
Bernardi, M | 1 |
Smith, IK | 1 |
Williams, R | 1 |
Susic, D | 1 |
Sparks, JC | 1 |
Vaz, AJ | 1 |
Takahashi, H | 1 |
Shibuya, Y | 1 |
Hayashida, Y | 1 |
Neale, TJ | 1 |
Lynn, KL | 1 |
Bailey, RR | 1 |
Rowe, WS | 1 |
Birkenhäger, WH | 1 |
Wester, A | 1 |
Iacona, A | 1 |
Rossetti, A | 1 |
Filingeri, V | 1 |
Orsini, D | 1 |
Cesarini, A | 1 |
Cervelli, V | 1 |
Adorno, D | 1 |
Casciani, CU | 1 |
McGeown, MG | 1 |
Morris, RG | 1 |
Frewin, DB | 1 |
Taylor, WB | 1 |
Glistak, ML | 1 |
Lehmann, DR | 1 |
Hänze, S | 1 |
Pierach, CA | 1 |
Stark, G | 1 |
Beilin, LJ | 1 |
Schiffman, N | 1 |
Crane, M | 1 |
Nelson, DH | 1 |
Brackett, NC | 2 |
Koppel, M | 1 |
Randall, RE | 1 |
Nixon, WP | 1 |
Sutherland, LE | 1 |
Hartroft, P | 1 |
Balis, JU | 1 |
Bailey, JD | 1 |
Lynch, MJ | 1 |
Desmit, EM | 1 |
Cost, WS | 1 |
Brown, JJ | 1 |
Fraser, R | 1 |
Lever, AF | 1 |
Robertson, JI | 1 |
Arant, BS | 1 |
Young, RB | 1 |
Still, WJ | 1 |
Ramanathan, K | 1 |
Gantt, C | 1 |
Grossman, A | 1 |
Modlinger, RS | 1 |
Nicolis, GL | 1 |
Krakoff, LR | 1 |
Gabrilove, JL | 1 |
Nakada, T | 1 |
Momose, G | 1 |
Yoshida, T | 1 |
Tateno, Y | 1 |
Shigematsu, H | 1 |
Selye, H | 1 |
Mantero, F | 1 |
Armanini, D | 1 |
Urbani, S | 1 |
Lagrue, G | 1 |
Fournier, A | 1 |
Jones, J | 1 |
Mills, IH | 1 |
Schmidt, P | 1 |
Kopsa, H | 1 |
Kronenberg, KH | 1 |
Meyer, D | 1 |
Zazgornik, J | 1 |
Kotzaurek, R | 1 |
Neumann, E | 1 |
Olbing, H | 1 |
Greifer, I | 1 |
Bennett, BP | 1 |
Bernstein, J | 1 |
Spitzer, A | 1 |
Dehart, HS | 1 |
Bath, NM | 1 |
Glenn, JF | 1 |
Gunnells, JC | 1 |
Cannon, PJ | 1 |
Leeming, JM | 1 |
Sommers, SC | 1 |
Winters, RW | 1 |
Laragh, JH | 1 |
Gekle, D | 1 |
Wernze, H | 1 |
Langer, KH | 1 |
Fanconi, A | 1 |
Schachenmann, G | 1 |
Nüssli, R | 1 |
Prader, A | 1 |
Levitt, JI | 1 |
Buckalew, VM | 1 |
Gall, G | 1 |
Vaitukaitis, J | 1 |
Haddow, JE | 1 |
Klein, R | 1 |
Stefan, H | 1 |
Helge, H | 1 |
Merker, HJ | 1 |
Bachmann, D | 1 |
Herman, E | 1 |
Rado, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
Genetic Predisposition of Chronic Nephrotoxicity From Calcineurin Inhibitors in Liver Transplant Recipients, Potential Correlation With Urinary Biomarkers[NCT00857844] | 207 participants (Actual) | Observational | 2007-07-31 | Completed | |||
Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
A Double-Blind, Placebo-Controlled Study on the Effect of Spironolactone, in Patients With Persistent Proteinuria on Long-Term Angiotensin Converting Enzyme Inhibitor Therapy, With or With Out an Angiotensin II Receptor Blocker[NCT00106561] | Phase 2/Phase 3 | 60 participants | Interventional | 2002-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
22 reviews available for spironolactone and Kidney Diseases
Article | Year |
---|---|
A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes.
Topics: Blood Glucose; Blood Pressure; Diabetes Complications; Humans; Hypertension; Inflammation; Kidney; K | 2021 |
Eplerenone's role in the management of complex cardiovascular disorders.
Topics: Cardiovascular Diseases; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists | 2015 |
Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury.
Topics: Aldosterone; Animals; Eplerenone; Humans; Kidney; Kidney Diseases; Mitogen-Activated Protein Kinases | 2008 |
[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system].
Topics: Aldosterone; Animals; Chronic Disease; Eplerenone; Humans; Kidney Diseases; Metabolic Syndrome; Mine | 2010 |
Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.
Topics: Aldosterone; Animals; Blood Pressure; Electrolytes; Eplerenone; Homeostasis; Humans; Kidney; Kidney | 2011 |
Mineralocorticoid receptor antagonist for renal protection.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Eplerenone; Humans; Kidn | 2012 |
Clinical implications of aldosterone blockade.
Topics: Aldosterone; Antihypertensive Agents; Black People; Blood Pressure; Cardiovascular Diseases; Clinica | 2002 |
Eplerenone, a new selective aldosterone blocker.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular System; Disease Model | 2003 |
RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.
Topics: Aldosterone; Cardiovascular Diseases; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Recepto | 2003 |
MANAGEMENT OF RENAL DYSFUNCTION IN CONGESTIVE HEART FAILURE.
Topics: Acetazolamide; Benzothiadiazines; Chlorthalidone; Diuretics; Heart Failure; Humans; Kidney Diseases; | 1963 |
[MECHANISM OF ACTION AND CLINICAL USE OF DIURETICS].
Topics: Bendroflumethiazide; Benzothiadiazines; Chlorothiazide; Chlorthalidone; Diuretics; Hydrochlorothiazi | 1963 |
[Roll of aldosterone in pathogenesis of kidney disorders].
Topics: Aldosterone; Animals; Body Water; Disease Models, Animal; Eplerenone; Humans; Hypertension; Kidney D | 2005 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade.
Topics: Aldosterone; Animals; Cell Proliferation; Cell Shape; Cells, Cultured; Collagen; Eplerenone; Fibrobl | 2006 |
[The importance of the biliary excretion of drugs in the human].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bile; Biological Transport; Cardiac Glycosides; Contra | 1983 |
Sodium and hypertension. A review of the role of sodium in pathogenesis and the action of diuretic drugs.
Topics: Age Factors; Aldosterone; Amiloride; Benzothiadiazines; Diuretics; Furosemide; Humans; Hypertension; | 1980 |
Diuretics in infancy.
Topics: Acute Disease; Benzothiadiazines; Diet, Sodium-Restricted; Diuretics; Diuretics, Osmotic; Edema; Eth | 1981 |
Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Drug Industry; Edema; Humans; Kidney Diseases; Minera | 2000 |
Aldosterone as a determinant of cardiovascular and renal dysfunction.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Endothelium, Vascular; Fibrosis; Huma | 2001 |
Eplerenone (GD Searle & Co).
Topics: Animals; Antihypertensive Agents; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hyper | 2001 |
Renin and hypertension: a review article.
Topics: Aldosterone; Humans; Hydrochlorothiazide; Hypertension; Juxtaglomerular Apparatus; Kidney Diseases; | 1973 |
Primary hyperaldosteronism.
Topics: Adrenal Gland Neoplasms; Aldosterone; Corticosterone; Desoxycorticosterone; Electrocardiography; Hum | 1974 |
Juxtaglomerular cell hyperplasia and secondary hyperaldosteronism (Bartter's syndrome): a re-evaluation of the pathophysiology.
Topics: Acid-Base Equilibrium; Adolescent; Adult; Aldosterone; Child; Child, Preschool; Female; Humans; Hype | 1968 |
14 trials available for spironolactone and Kidney Diseases
Article | Year |
---|---|
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; | 2021 |
Galectin-3 in patients with atrial fibrillation and restored sinus rhythm.
Topics: Aged; Atrial Fibrillation; Biomarkers; Female; Fibrosis; Galectin 3; Gout; Humans; Kidney Diseases; | 2021 |
Spironolactone attenuates oxidative stress in patients with chronic kidney disease.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antioxidan | 2008 |
Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2009 |
Spironolactone in chronic hemodialysis patients improves cardiac function.
Topics: Aged; Chronic Disease; Diuretics; Double-Blind Method; Female; Heart Failure; Humans; Hyperkalemia; | 2009 |
Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Dru | 2010 |
Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effect
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2010 |
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec | 2010 |
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec | 2010 |
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec | 2010 |
Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
Topics: Chronic Disease; Diastole; Female; Humans; Kidney Diseases; Male; Middle Aged; Mineralocorticoid Rec | 2010 |
Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chronic Disease; Double-Blind Method; Drug Resistanc | 2011 |
Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Creatinine; Eplerenone; Female; Humans; Hyperka | 2005 |
Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C | 2008 |
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Topics: Acetylglucosaminidase; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Diuresis in the ascitic patient: a randomized controlled trial of three regimens.
Topics: Ascites; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Furosemide; Hepat | 1981 |
106 other studies available for spironolactone and Kidney Diseases
Article | Year |
---|---|
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line, Tumor; Chlorobenzenes; Crystallography, | 2010 |
Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardi | 2021 |
Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction.
Topics: Erythrocyte Indices; Heart Failure; Humans; Kidney Diseases; Spironolactone; Stroke Volume | 2023 |
Aldosterone: The Missing Cardiorenal Link.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Heart Diseases; Humans; Kidney Diseases; Mine | 2019 |
Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats.
Topics: Animals; Catalase; Cytokines; Glutathione; Kidney; Kidney Diseases; Losartan; Male; Rats, Wistar; Re | 2020 |
Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat.
Topics: Aldosterone; Animals; Blood Pressure; Disease Models, Animal; Fibrosis; Hypertension; Kidney Disease | 2020 |
New insights on the renal protective effects of mineralocorticoid receptor antagonists.
Topics: Humans; Kidney; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoi | 2019 |
Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Topics: Animals; Antibodies; Desoxycorticosterone Acetate; Disease Models, Animal; Down-Regulation; Forkhead | 2014 |
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Topics: Animals; Autoradiography; Cardiomegaly; Disease Models, Animal; Eplerenone; Heart Failure; Kidney Di | 2014 |
Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Topics: Adrenalectomy; Aldosterone; Animals; Chronic Disease; Cyclosporine; Cytochrome P-450 CYP11B2; Diseas | 2015 |
Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats.
Topics: Aldosterone; Animals; Fibrosis; Inflammation; Kidney; Kidney Diseases; Macrophages; Male; Mineraloco | 2016 |
Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats.
Topics: Animals; Epithelial-Mesenchymal Transition; Heart Failure; Kidney Diseases; Rats; Spironolactone; Tr | 2016 |
Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice.
Topics: Aldosterone; Animals; Blood Pressure; Fibrosis; Humans; Interleukin-18; Kidney; Kidney Diseases; Mal | 2016 |
Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats.
Topics: Animals; Fibrosis; Hemodynamics; Inflammation; Kidney Diseases; Male; NG-Nitroarginine Methyl Ester; | 2009 |
The Janus effect: two faces of aldosterone.
Topics: Adrenal Cortex Hormones; Aldosterone; Animals; Humans; Kidney Diseases; NG-Nitroarginine Methyl Este | 2009 |
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.
Topics: Angiotensin II; Animals; Cytochrome P-450 CYP11B2; Enzyme Inhibitors; Fibrosis; Heart Diseases; Kidn | 2009 |
Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; Cell | 2009 |
Aldosterone in clinical nephrology--old hormone, new questions.
Topics: Aldosterone; Eplerenone; Humans; Hypertension; Kidney Diseases; Mineralocorticoid Receptor Antagonis | 2009 |
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cell Hypoxia | 2009 |
Safety of spironolactone use in ambulatory heart failure patients.
Topics: Aged; Ambulatory Care; Biomarkers; Chronic Disease; Creatinine; Evidence-Based Medicine; Female; Hea | 2009 |
Adrenalectomy prevents renal ischemia-reperfusion injury.
Topics: Adrenalectomy; Aldosterone; Animals; Kidney; Kidney Diseases; Male; Nitric Oxide; Nitric Oxide Synth | 2009 |
Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies--the effect on podocytes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Drug Therapy, Combination; Kidney Diseases; Male; | 2009 |
Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease.
Topics: Aldosterone; Androstenes; Animals; Blood Pressure; Epithelial Sodium Channels; Estradiol; Female; Hy | 2009 |
Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.
Topics: Aortic Diseases; Chronic Disease; Humans; Hyperkalemia; Hypertrophy, Left Ventricular; Kidney Diseas | 2009 |
Spironolactone therapy in heart failure patients with chronic kidney disease.
Topics: Biomarkers; Chronic Disease; Creatinine; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Miner | 2009 |
Renoprotective effects of mineralocorticoid receptor blockade in heminephrectomized (pro)renin receptor transgenic rats.
Topics: Aldosterone; Animals; Eplerenone; Humans; Kidney Diseases; Mineralocorticoid Receptor Antagonists; N | 2010 |
Eplerenone in chronic renal disease: the EVALUATE trial.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Clinical Trials as Topic; Eplerenone; Female; Human | 2010 |
Kidney impairment in primary aldosteronism.
Topics: Glomerular Filtration Rate; Humans; Hyperaldosteronism; Hypertension; Kidney Diseases; Logistic Mode | 2011 |
Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-γ).
Topics: Animals; Blood Pressure; Connective Tissue Growth Factor; Cytokines; Down-Regulation; Eplerenone; Ge | 2011 |
Protective effects of eplerenone on podocyte injury in adriamycin nephropathy rats.
Topics: Animals; Cytokines; Down-Regulation; Doxorubicin; Eplerenone; Kidney Diseases; Kidney Glomerulus; Ma | 2011 |
Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Topics: Acute Kidney Injury; Aged; Alabama; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2012 |
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Biomarkers; Blood Pressure; Cytochrome P-450 CYP11B2; D | 2012 |
Targeting activated mineralocorticoid receptor: Occam's razor revisited.
Topics: Aldosterone; Angiotensin II; Animals; Heart Diseases; Kidney Diseases; Mineralocorticoid Receptor An | 2012 |
Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Cohort Studies; Comorbidity; Disease Progression; Fe | 2013 |
Liddle syndrome in a newborn infant.
Topics: Alkalosis; Amiloride; Blood Pressure; Diuretics; Electrolytes; Failure to Thrive; Female; Humans; Hy | 2002 |
Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Diuretics; Drug Thera | 2002 |
Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.
Topics: Aldosterone; Animals; Chronic Disease; Collagen Type I; Collagen Type IV; Cyclosporine; Fibronectins | 2003 |
Early aldosterone up-regulated genes: new pathways for renal disease?
Topics: Aldosterone; Blotting, Northern; Blotting, Western; CCAAT-Enhancer-Binding Proteins; Cells, Cultured | 2003 |
Effect of a steroid spirolactone on the cardiovascular changes produced by renal ischemia.
Topics: Aldosterone; Cardiovascular System; Diuretics; Kidney Diseases; Mineralocorticoid Receptor Antagonis | 1961 |
Use of spironolactone in renal edema. Effectiveness and association with hyperkalemia.
Topics: Aldosterone; Diuretics; Edema; Humans; Hyperkalemia; Kidney; Kidney Diseases; Mineralocorticoid Rece | 1961 |
Hyperkalemia and sudden death during Spironolactone (Aldactone) therapy.
Topics: Death, Sudden; Humans; Hyperkalemia; Kidney Diseases; Liver Diseases; Spironolactone | 1962 |
[Histological study of the adrenal glomerular zone, the epiphysis, diencephalic neurosecretion and the juxtaglomerular apparatus of white rats subjected to the effects of a thioacetylated spirolactone].
Topics: Animals; Diencephalon; Epiphyses; Juxtaglomerular Apparatus; Kidney Diseases; Kidney Glomerulus; Neu | 1962 |
[Spirolactone and lipoprotein metabolism in nephropathy in pregnancy].
Topics: Blood Proteins; Edema; Female; Hypertension; Hypertension, Renal; Kidney; Kidney Diseases; Lipoprote | 1962 |
[THE TREATMENT OF EDEMA WITH SULFONAMIDE DIURETICS].
Topics: Acetazolamide; Acidosis; Benzothiadiazines; Chlorothiazide; Chlorthalidone; Dehydration; Diuretics; | 1964 |
SPIRONOLACTONE AND PLASMA CORTISOL.
Topics: Blood Chemical Analysis; Humans; Hydrocortisone; Kidney Diseases; Pharmacology; Rheumatic Heart Dise | 1964 |
HYPERTENSION AND HYPERPOTASSAEMIA WITHOUT RENAL DISEASE IN A YOUNG MALE.
Topics: Adolescent; Chlorides; Drug Therapy; Humans; Hyperkalemia; Hypertension; Kidney Diseases; Kidney Fun | 1964 |
STUDIES ON ETHACRYNIC ACID IN PATIENTS WITH REFRACTORY EDEMA.
Topics: Alkalosis; Blood; Chlorides; Creatine; Creatinine; Diuretics; Drug Therapy; Edema; Ethacrynic Acid; | 1965 |
HYPERTENSION AND HYPERALDOSTERONISM OF RENAL AND ADRENAL ORIGIN.
Topics: Adolescent; Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenalectomy; Blood; Child; Diagnosis, | 1965 |
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Coronary Artery Disease; Disease Mode | 2003 |
Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.
Topics: Aged; Aged, 80 and over; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Ma | 2003 |
Influence of spironolactone treatment on gentamicin-induced nephrotoxicity in rats.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Body Weight; Creatinine; Drug Synergism; Genta | 2004 |
How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Creatinine; Denmark; | 2004 |
Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases.
Topics: Angiotensin Receptor Antagonists; Diabetic Nephropathies; Female; Humans; Kidney Diseases; Male; Mid | 2004 |
[Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure. A retrospective analysis of 125 consecutive cases].
Topics: Aged; Aged, 80 and over; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Kidney Diseases; Ma | 2004 |
Hyperkalemia after the publication of RALES.
Topics: Creatinine; Heart Failure; Hospitalization; Humans; Hyperkalemia; Kidney Diseases; Mineralocorticoid | 2004 |
[The 10-minute consultation. Accidental finding: hyperkalemia. Caution with analgesics and bananas].
Topics: Aged; Analgesics; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Coronary Disease; Diabetes Melli | 2005 |
Cardiorenal abnormalities associated with high sodium intake: correction by spironolactone in rats.
Topics: Administration, Oral; Animals; Blood Pressure; Body Weight; Cardiomegaly; Diuretics; Drug Interactio | 2005 |
Gitelman's syndrome presenting as intolerance to statin therapy.
Topics: Adult; Amiloride; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutar | 2005 |
Gitelman's syndrome with silent thyroiditis.
Topics: Adult; Calcium; Female; Humans; Hypokalemia; Kidney Diseases; Magnesium; Muscular Diseases; Spironol | 2006 |
Long-term renal outcomes in patients with primary aldosteronism.
Topics: Adrenalectomy; Adult; Albuminuria; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism; H | 2006 |
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.
Topics: Animals; Apoptosis; Arterioles; Blood Pressure; Body Weight; Caspase 3; Cell Adhesion Molecules; Cyc | 2007 |
Spironolactone with ACE inhibitor is effective in gross hematuria caused by nephroptosis.
Topics: Biopsy; Diagnosis, Differential; Female; Follow-Up Studies; Hematuria; Humans; Kidney; Kidney Diseas | 2006 |
Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone.
Topics: Aldosterone; Animals; Blotting, Western; Catalase; Glutathione Peroxidase; Immunohistochemistry; In | 2007 |
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cyclic N-Oxides; Disease Models, Animal; Eplerenone; Hypertensio | 2007 |
Lasix.
Topics: Diuresis; Edema; Furosemide; Heart Failure; Humans; Kidney Diseases; Liver Cirrhosis; Potassium Defi | 1967 |
Changes in plasma renin activity after administration of spironolactone.
Topics: Adolescent; Adult; Aortic Coarctation; Blood Pressure; Cushing Syndrome; Female; Glomerulonephritis; | 1967 |
[The behavior of uricemia during treatment with spironolactone and with other diuretics].
Topics: Acetazolamide; Adolescent; Adult; Aged; Chlorthalidone; Clopamide; Diuretics; Ethacrynic Acid; Femal | 1967 |
[Therapy of cardiac insufficiency with diuretics].
Topics: Amiloride; Benzothiadiazines; Blood Glucose; Diuretics; Drug Administration Schedule; Female; Furose | 1982 |
Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome.
Topics: Adult; Aldosterone; Amiloride; Bartter Syndrome; Blood Gas Analysis; Blood Pressure; Creatinine; Dru | 1994 |
Role of aldosterone in the remnant kidney model in the rat.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biph | 1996 |
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Drug Therapy, Combination; E | 2001 |
Effect of spironolactone on cisplatin-induced nephrotoxicity in rabbits.
Topics: Animals; Antineoplastic Agents; Cisplatin; Diuretics; Drug Therapy, Combination; Kidney Diseases; Ki | 2001 |
Spironolactone and ACE inhibition in chronic renal failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Drug Therapy, Combination; Humans; Hyperte | 2002 |
Diuretic-induced renal impairment without volume depletion in cirrhosis: changes in the renin-angiotensin system and the effect of beta-adrenergic blockade.
Topics: Adrenergic beta-Antagonists; Adult; Creatinine; Female; Furosemide; Humans; Kidney; Kidney Diseases; | 1979 |
Differentiation of nephrotensin from the renin angiotensin system.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodies; Atropine; Biological | 1975 |
Clinical use of spironolactone.
Topics: Diabetes Complications; Humans; Hyperkalemia; Kidney Diseases; Spironolactone | 1979 |
Preventive mechanism of spironolactone against mercury-induced renal damage: role of metallothionein.
Topics: Animals; Kidney; Kidney Diseases; Male; Mercury; Mercury Poisoning; Metalloproteins; Metallothionein | 1979 |
[Study on potassium transport in the intestine compensatory potassium excretion mechanism increasing factors of potassium secretion (author's transl)].
Topics: Aldosterone; Animals; Biological Transport; Humans; Intestinal Mucosa; Kidney Diseases; Male; Postur | 1978 |
Spironolactone-associated aggravation of renal functional impairment.
Topics: Aged; Female; Humans; Hyperkalemia; Kidney Diseases; Middle Aged; Spironolactone | 1976 |
Some aspects of the management of hypertension II. Special considerations.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Determination; Diazoxide; Drug Therapy, Combina | 1975 |
[A question of logic].
Topics: Diazoxide; Furosemide; Humans; Hyperaldosteronism; Hypertension; Kidney Diseases; Male; Middle Aged; | 1976 |
Reduced nephrotoxicity and hepatoxicity in cyclosporin A therapy by enalapril and spironolactone in rats.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cyclosporine; Drug Therapy, Combination; Enalapril; | 1991 |
Spironolactone and hyperkalaemia in patients with impaired renal failure.
Topics: Humans; Hyperkalemia; Kidney Diseases; Spironolactone | 1987 |
The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassays.
Topics: Aged; Aged, 80 and over; Digoxin; Female; Humans; Immunoassay; Kidney Diseases; Liver Diseases; Male | 1988 |
[Bartter syndrome. Vascular angiotensin II resistance with juxtaglomerular cellular hyperplasia and hyperaldosteronism].
Topics: Adult; Angiotensin II; Humans; Hyperaldosteronism; Hyperplasia; Hypokalemia; Kidney Diseases; Potass | 1965 |
Hypokalaemic alkalosis and hyperplasia of the juxtaglomerular apparatus without hypertension or oedema.
Topics: Adolescent; Alkalosis; Angiotensin II; Blood Pressure; Extracellular Space; Humans; Hyperaldosteroni | 1967 |
Hyperplasia of the juxtaglomerular complex with secondary aldosteronism without hypertension (Bartter's syndrome).
Topics: 17-Ketosteroids; Adrenocorticotropic Hormone; Aldosterone; Ammonium Chloride; Angiotensin II; Bicarb | 1968 |
Bartter's syndrome. A report of four cases, including three in one sibship, with comparative histologic evaluation of the juxtaglomerular apparatuses and glomeruli.
Topics: Alkalosis; Angiotensin II; Blood Pressure; Carbon Dioxide; Cerebrospinal Fluid Proteins; Electrolyte | 1970 |
An unusual type of hypokalaemic alkalosis with a disturbance of renin and aldosterone.
Topics: Adolescent; Adrenal Cortex Hormones; Albumins; Aldosterone; Alkalosis; Angiotensin II; Creatinine; D | 1970 |
Case studies of siblings with juxtaglomerular hyperplasia and secondary aldosteronism associated with severe azotemia and renal rickets--Bartter's syndrome or disease?
Topics: Aldosterone; Alkalosis; Angiotensin II; Bone Diseases; Child; Child, Preschool; Humans; Hyperaldoste | 1970 |
Six year follow-up of a child with Bartter syndrome.
Topics: Aldosterone; Alkalosis; Angiotensin II; Biopsy; Blood Pressure; Child, Preschool; Diet Therapy; Fema | 1973 |
Some observations on the pathogenesis of Bartter's syndrome.
Topics: Adult; Aldosterone; Alkalosis; Angiotensin II; Blood Volume; Drug Therapy, Combination; Humans; Hype | 1973 |
Renin-angiotensin-aldosterone system of a woman with Bartter's syndrome: Juxtaglomerular cell hyperplasia without hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; Humans; Hyperaldosteronism; Hyp | 1974 |
Protection by glucocorticoids against allopurinol nephropathy.
Topics: Allopurinol; Animals; Desoxycorticosterone; Estradiol; Ethylestrenol; Female; Kidney; Kidney Disease | 1972 |
Antihypertensive effect of spironolactone in essential, renal and mineralocorticoid hypertension.
Topics: Adult; Aldosterone; Female; Humans; Hyperaldosteronism; Hypertension; Hypertension, Renal; Kidney Di | 1973 |
[Nephrology in 1972].
Topics: Bone Resorption; Calcium; Dextrans; Female; Fluorescent Antibody Technique; Gentamicins; Glomerulone | 1972 |
[Bartter's syndrome in adults. Case report with light- and electron-microscopic findings].
Topics: Adult; Alkalosis; Female; Humans; Hyperaldosteronism; Hyperplasia; Hypertrophy; Hypokalemia; Hypoten | 1973 |
Idiopathic membranous nephropathy in children.
Topics: Adolescent; Age Factors; Aminohippuric Acids; Basement Membrane; Biopsy; Child; Child, Preschool; Cr | 1973 |
Urologic considerations in Bartter's syndrome.
Topics: Adolescent; Adult; Biopsy; Carpal Bones; Female; Foot; Humans; Hydronephrosis; Hyperaldosteronism; H | 1974 |
[Problems in Bartter's syndrome].
Topics: Alkalosis; Biopsy; Child, Preschool; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism; | 1971 |
Chronic hypokalaemia with growth retardation, normotensive hyperrenin-hyperaldosteronism ("Bartter's syndrome"), and hypercalciuria. Report of two cases with emphasis on natural history and on catch-up growth during treatment.
Topics: Alkalosis; Calcium; Child; Chronic Disease; Female; Growth Disorders; Humans; Hyperaldosteronism; Hy | 1971 |
Spironolactone therapy and amenorrhea.
Topics: Adult; Amenorrhea; Female; Humans; Kidney Diseases; Menstruation Disturbances; Spironolactone | 1970 |
Clinical usage of the newer diuretic agents.
Topics: Diuretics; Ethacrynic Acid; Furosemide; Humans; Hypokalemia; Kidney Diseases; Spironolactone; Triamt | 1970 |
Erythrocyte Na flux in a patient with Bartter's syndrome.
Topics: Aldosterone; Alkalosis; Ammonium Chloride; Biological Transport; Biological Transport, Active; Cell | 1971 |
[Kidney artery stenosis, renal hypertension and secondary hyperaldosteronism in an 8-year-old boy. (Stunted growth through potassium deficiency)].
Topics: Adrenal Glands; Aldosterone; Child; Dwarfism; Humans; Hyperaldosteronism; Hypertension, Renal; Hypok | 1968 |
Fatal hyperkalemic paralysis associated with spironalactone. Observation on a patient with severe renal disease and refractory edema.
Topics: Adult; Diabetes Mellitus; Diabetic Nephropathies; Edema; Heart Failure; Humans; Hyperkalemia; Hypert | 1966 |